Donoghue Forlines
VRTX icon

Donoghue Forlines’s Vertex Pharmaceuticals VRTX Stock Holding History

Donoghue Forlines’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$933K Buy
+1,784
New +$913K 0.24% 119
2024
Q3 		– Sell
-3,323
Closed -$1.56M – 275
2024
Q2 		$1.56M Sell
3,323
-434
-12% -$188K 0.44% 49
2024
Q1 		$1.57M Buy
3,757
+2,357
+168% +$996K 0.45% 68
2023
Q4 		$570K Sell
1,400
-3,896
-74% -$1.44M 0.18% 151
2023
Q3 		$1.84M Sell
5,296
-169
-3% -$59.1K 0.66% 25
2023
Q2 		$1.92M Sell
5,465
-94
-2% -$31.7K 0.6% 25
2023
Q1 		$1.75M Buy
5,559
+74
+1% +$22.2K 0.63% 24
2022
Q4 		$1.58M Buy
5,485
+1,517
+38% +$462K 0.56% 36
2022
Q3 		$1.15M Buy
3,968
+213
+6% +$61.3K 0.41% 24
2022
Q2 		$1.06M Buy
3,755
+527
+16% +$141K 0.28% 83
2022
Q1 		$842K Buy
+3,228
New +$766K 0.18% 179
2021
Q3 		– Sell
-5,151
Closed -$1.04M – 245
2021
Q2 		$1.04M Buy
5,151
+345
+7% +$72.2K 0.19% 133
2021
Q1 		$1.03M Buy
4,806
+11
+0.2% +$2.42K 0.2% 129
2020
Q4 		$1.13M Buy
+4,795
New +$1.1M 0.22% 117

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Donoghue Forlines's VRTX Position: Q3 2026 in Review

Donoghue Forlines opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 1,784 shares worth $933K. The stake represents 0.24% of the portfolio and ranks #119 among its holdings. This is a return to the name: Donoghue Forlines previously reported a position in VRTX as recently as Q2 2024.

Donoghue Forlines first reported a position in VRTX in Q4 2020 and has held it in 14 quarters since. The position peaked at $1.92M in Q2 2023. 1,128 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Donoghue Forlines held 1,784 shares of Vertex Pharmaceuticals worth $933K as of Q3 2026.
  • Vertex Pharmaceuticals was a new Donoghue Forlines position in Q3 2026.
  • Vertex Pharmaceuticals made up 0.24% of Donoghue Forlines's portfolio in Q3 2026, its #119 holding.
  • Donoghue Forlines first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
  • Donoghue Forlines's Vertex Pharmaceuticals position peaked at $1.92M in Q2 2023.
  • 1,128 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Donoghue Forlines's 13F filing for Q3 2026, filed 2 Nov 2026.